Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
SS-31 (Elamipretide) (SS31) is a anti-aging peptide, at the clinical trials stage in the published literature. Mitochondria-targeted tetrapeptide that improves mitochondrial function and reduces oxidative stress. In clinical trials for heart failure.
Mitochondria-targeted tetrapeptide that improves mitochondrial function and reduces oxidative stress. In clinical trials for heart failure.
| Research Status | Clinical trials |
|---|---|
| Half-Life | ~1 hour |
| Administration | Subcutaneous or IV injection |
| Doses Reported in Published Studies | 0.25-4 mg/kg |
Targets cardiolipin in mitochondrial inner membrane, stabilizing electron transport and reducing ROS production.
Mitochondria-targeted tetrapeptide that improves mitochondrial function and reduces oxidative stress. In clinical trials for heart failure.
Targets cardiolipin in mitochondrial inner membrane, stabilizing electron transport and reducing ROS production.
SS-31 (Elamipretide) is at the following stage in the published literature: Clinical trials. All information is for research and educational purposes only.
Reported half-life: ~1 hour.
Reported administration route in the literature: Subcutaneous or IV injection. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.